Suppr超能文献

用于检测点突变的连接酶链反应(LCR)的评估。

Evaluation of the ligase chain reaction (LCR) for the detection of point mutations.

作者信息

Kälin I, Shephard S, Candrian U

机构信息

Institute of Toxicology, Swiss Federal Institute of Technology, Schwerzenbach/Zürich.

出版信息

Mutat Res. 1992 Oct;283(2):119-23. doi: 10.1016/0165-7992(92)90143-6.

Abstract

The ligase chain reaction (LCR) was evaluated as an amplification method for an in vivo mutation assay. Specifically, the ligase was tested for its ability to selectively amplify a DNA sequence mutated at a single base, in the presence of an excess of wild-type DNA. As a model template a 370-bp DNA fragment of the mouse Ha-ras protooncogene containing an A to T mutation at the second position of codon 61 was used. With the commercially available ligase Ampligase (Epicenter), 250 molecules of mutant fragments could be detected by an enzyme-linked immunoassay with digoxigenin marker (giving a theoretical detection limit of 1 target gene per 10(4) copies of genome). In the analysis of mixtures with corresponding wild-type DNA fragments, a 1:1 mixture resulted in a clearly stronger signal than control samples lacking wild-type and mutant DNA. However, the signal obtained from a 100-fold dilution of the mutant DNA with wild-type DNA could not be distinguished from the background noise. In this particular form, LCR lacks sufficient selectivity to be applied to an in vivo situation, where the ratio of mutant to wild-type DNA sequences might be expected to lie around 1:10(6).

摘要

连接酶链式反应(LCR)被评估作为一种用于体内突变分析的扩增方法。具体而言,在存在过量野生型DNA的情况下,测试连接酶选择性扩增在单个碱基处发生突变的DNA序列的能力。使用小鼠Ha-ras原癌基因的一个370bp DNA片段作为模型模板,该片段在密码子61的第二位存在A到T的突变。使用市售的连接酶Ampligase(Epicenter),通过地高辛标记的酶联免疫测定法可检测到250个突变片段分子(理论检测限为每10⁴个基因组拷贝中有1个靶基因)。在分析与相应野生型DNA片段的混合物时,1:1的混合物产生的信号明显强于缺乏野生型和突变型DNA的对照样品。然而,从突变型DNA与野生型DNA以100倍稀释得到的信号无法与背景噪声区分开来。以这种特定形式,LCR缺乏足够的选择性以应用于体内情况,在体内情况下,突变型与野生型DNA序列的比例可能预计在1:10⁶左右。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验